According to the CRC staging in the 8th edition of AJCC, serum carcinoembryonic antigen (CEA) levels, RAS, BRAF gene mutations, microsatellite instability, and tumor regression scores are recommended as molecular markers for predicting the prognosis risk and curative effect of CRC 3. Here, BRAF is linked to colorectal carcinoma.